Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-07-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of idle raised funds for cash management, specifically detailing the redemption of a structured deposit and continuation of cash management activities. It includes information about the investment product, amounts, dates, approvals by the board, risk disclosures, and references to previous related announcements. The document is relatively short (3498 characters) and primarily serves as a disclosure/update about the company's cash management activities using idle raised funds. It does not contain comprehensive financial statements, detailed financial performance data, or management analysis typical of annual or interim reports. It also does not fit categories like earnings release, board changes, or legal proceedings. The content aligns with a Capital/Financing Update (CAP) as it relates to the company's use of raised capital for cash management and investment activities. Therefore, the appropriate classification is CAP with high confidence.
2025-07-01 Chinese
奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related changes in share capital. It includes details about the issuance, listing, and conversion status of convertible bonds, as well as the impact on the company's share capital. The document is titled as an announcement and contains specific data on bond conversions and share changes but does not present a full financial report or detailed financial statements. It is a regulatory announcement about capital changes due to convertible bond conversions, fitting the category of Share Issue/Capital Change (SHA). The document length is short (2008 characters), consistent with an announcement rather than a full report.
2025-07-01 Chinese
奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, detailing the number of shares repurchased, the price range, the total amount spent, and the purpose of the repurchase (conversion of convertible bonds). It references previous announcements and regulatory compliance but does not contain financial statements or detailed financial analysis. The document length is 1817 characters, which is relatively short and focused on the update of share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2025-07-01 Chinese
奥锐特药业股份有限公司相关债券2025年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report for 奥锐特药业股份有限公司 related to its bonds maturing in 2025. It includes extensive financial data, company operational and competitive analysis, industry environment, macroeconomic outlook, bond issuance and usage of proceeds, shareholder information, and risk factors. The document is titled as a "跟踪评级报告" (tracking rating report) and contains comprehensive financial and operational analysis rather than just an announcement or summary. It is not an annual or quarterly report filed by the company itself, but rather a credit rating agency's independent evaluation report. This type of document does not fit into categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is a standalone credit rating report, which aligns best with the category Audit Report / Information (AR) as it involves an independent assessment of financial and credit status, including financial data and risk analysis, but is not a full annual report. Therefore, the most appropriate classification is AR (Audit Report / Information). The document length (15,000 characters) and detailed content support this classification with high confidence. Q1 2025
2025-06-27 Chinese
奥锐特药业股份有限公司关于“奥锐转债”2025年跟踪信用评级结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the tracking credit rating result of a convertible bond issued by the company. It includes details about previous and current credit ratings, the rating agency, and references a detailed rating report available on the stock exchange website. The document is short (726 characters) and primarily serves to inform about the rating update rather than providing the full rating report itself. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain detailed financial statements or comprehensive report content.
2025-06-27 Chinese
国泰海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券受托管理事务报告（2024年度）
Audit Report / Information Classification · 95% confidence The document is a detailed report concerning the issuance and management of a convertible corporate bond by 奥锐特药业股份有限公司 (Aurisco Pharmaceutical Co., Ltd.) for the year 2024. It includes comprehensive information about the bond issuance approval, terms, interest rates, conversion price adjustments, redemption and repurchase clauses, bondholder rights and obligations, financial data of the issuer for 2024, use of raised funds, and trustee management activities. The document is lengthy (15,000 characters) and contains substantive financial data, operational details, and compliance information related to the bond issuance and management. It is not a simple announcement or a brief summary but a full report on the bond issuance and its management for the year. This type of document fits the category of an Audit Report / Information (AR) because it includes audit opinions, financial data, and detailed regulatory compliance information related to the bond issuance, but it is not a full Annual Report (10-K) of the company. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed substantive content rather than just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2024
2025-06-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.